Chemotherapy News and Research

Latest Chemotherapy News and Research

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

You can teach an old drug new chemotherapy tricks. Northwestern University researchers took a drug therapy proven for blood cancers but ineffective against solid tumors, packaged it with nanotechnology and got it to combat an aggressive type of breast cancer prevalent in young women, particularly young African-American women.

16 Jul 2010

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

The medical standard of care - comprised of surgery, radiation and chemotherapy - for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

15 Jul 2010

Kidney Cancer Canada applauds Ontario for granting coverage for RCC therapy TORISEL

Ontario has taken a major step forward in access to treatment for patients in the province with advanced kidney cancer by granting coverage for TORISELTM (temsirolimus), for advanced renal cell carcinoma (RCC) with poor prognostic features.

15 Jul 2010

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

Researchers at the Keck School of Medicine of the University of Southern California (USC) will test whether a set of blood-based biomarkers can assist mammography in the early detection of breast cancer with a $180,000 grant announced today from Susan G. Komen for the Cure®. The grant will fund research into whether specific biomarkers, or minute substances in the blood, can effectively distinguish breast cancer patients from their healthy counterparts and whether an inexpensive, less invasive screening strategy can be developed based on this approach.

15 Jul 2010

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.

15 Jul 2010

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

The leukemia stem cell-the root cause of all acute leukemias- represents a small population of cells in patients that are difficult to eliminate with standard treatments available today. Though current chemotherapy can produce temporary remission in leukemia survivors, they remain at risk of experiencing a recurrence and dying from the disease.

15 Jul 2010

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Highlights of AAPM 52nd meeting

The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.

14 Jul 2010

Fredericksburg Oncology invites participants for new metastatic melanoma clinical trial

Fredericksburg Oncology is now accepting patients for a new clinical trial supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma. The current trial, designed at the Mayo Clinic, combines chemotherapy with targeted molecular agents in an effort to improve control of this difficult disease, reports Dr. Frederick C. Tucker, Jr., who heads this practice.

13 Jul 2010

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. The German CLL Study Group proved this in a multicentric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital.

13 Jul 2010

CSHL scientists reverse symptoms of Type III SMA using ASOs

The devastating, currently incurable motor-neuron disease spinal muscular atrophy might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides.

13 Jul 2010

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests.

13 Jul 2010

U.S. lags in keeping workers safe from toxic drugs

In many countries, there are strict regulations and inspections regarding workers who handle chemotherapy drugs. "In the U.S., however, neither environmental monitoring nor exposure tracking is mandated. And neither is routinely taking place, said Tom Conner, a research biologist with National Institute for Occupational Safety and Health (NIOSH).

13 Jul 2010

Bedford Laboratories launches Dactinomycin for Injection

Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products. Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc. Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.

12 Jul 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Jul 2010

MiCK assay effective in predicting best chemotherapy response for Endometrial Cancer patients: Study

Oncologists working with DiaTech Oncology have published the results of a comprehensive study to determine the effectiveness of the Microculture Kinetic (MiCK) assay for apoptosis in predicting the best chemotherapy response for Endometrial Cancer patients. (Journal of Gynecologic Oncology March 2010 Mar)

12 Jul 2010

AngioDynamics adds low-profile, mini models to Smart Port CT family of power-injectable ports

AngioDynamics announced today the global expansion of its Smart Port CT family of power-injectable ports, featuring its patented Vortex® port technology - to include low-profile and mini models for repeated treatments such as chemotherapy and for use with computed tomography (CT).

12 Jul 2010

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that a manuscript based on a study of Clarient InsightDx Mammostrat, a test used to classify the risk of recurrence of breast cancer following surgery and chemotherapy, will be published in an upcoming edition of Breast Cancer Research, a prominent peer-reviewed medical journal.

12 Jul 2010

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Head and neck cancer patients who reported poor sleep quality one year after diagnosis had more symptoms of chronic pain and complaints of dry mouth related to radiation treatments, according to a recent study from the University of Michigan Comprehensive Cancer Center.

12 Jul 2010

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Australian regenerative medicine company, Mesoblast Limited, today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration to discuss a proposed Phase 3 clinical trial program.

12 Jul 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

Kidney Cancer Canada applauds Ontario for granting coverage for RCC therapy TORISEL

Keck School of Medicine receives grant for research on biomarker impact on breast cancer screening

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Highlights of AAPM 52nd meeting

Fredericksburg Oncology invites participants for new metastatic melanoma clinical trial

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

CSHL scientists reverse symptoms of Type III SMA using ASOs

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

U.S. lags in keeping workers safe from toxic drugs

Bedford Laboratories launches Dactinomycin for Injection

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

MiCK assay effective in predicting best chemotherapy response for Endometrial Cancer patients: Study

AngioDynamics adds low-profile, mini models to Smart Port CT family of power-injectable ports

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Reducing chronic pain, dry mouth could improve quality of life in head and neck cancer patients: Study

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in